Denmark's Genmab in research collaboration with Eli Lilly
COPENHAGEN, Jan 14 (Reuters) - Danish biotech company Genmab has entered into a research collaboration with U.S. pharmaceutical company Eli Lilly involving its DuoBody technology platform.
The platform is used to discover and develop so-called bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease.
The financial terms of the agreement have not been disclosed, but Genmab stated that it would not have a material impact on its financial results and cash position.
(Reporting by Teis Jensen; Editing by Mark Potter)